JP2023553591A5 - - Google Patents
Info
- Publication number
- JP2023553591A5 JP2023553591A5 JP2023528227A JP2023528227A JP2023553591A5 JP 2023553591 A5 JP2023553591 A5 JP 2023553591A5 JP 2023528227 A JP2023528227 A JP 2023528227A JP 2023528227 A JP2023528227 A JP 2023528227A JP 2023553591 A5 JP2023553591 A5 JP 2023553591A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- lys
- glp
- amyrin
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20215291.4 | 2020-12-18 | ||
| EP20215291 | 2020-12-18 | ||
| EP21154668.4 | 2021-02-02 | ||
| EP21154668 | 2021-02-02 | ||
| EP21179810.3 | 2021-06-16 | ||
| EP21179810 | 2021-06-16 | ||
| PCT/EP2021/086494 WO2022129526A1 (en) | 2020-12-18 | 2021-12-17 | Co-agonists of the glp-1 and amylin receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023553591A JP2023553591A (ja) | 2023-12-25 |
| JP2023553591A5 true JP2023553591A5 (enExample) | 2024-01-12 |
| JP7554928B2 JP7554928B2 (ja) | 2024-09-20 |
Family
ID=79024591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528227A Active JP7554928B2 (ja) | 2020-12-18 | 2021-12-17 | Ｇｌｐ－１およびアミリン受容体の共作動薬 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US12054528B2 (enExample) |
| EP (1) | EP4263581A1 (enExample) |
| JP (1) | JP7554928B2 (enExample) |
| KR (3) | KR102667196B1 (enExample) |
| CN (4) | CN121975020A (enExample) |
| AU (2) | AU2021403851B2 (enExample) |
| CA (1) | CA3201088A1 (enExample) |
| CL (1) | CL2023001714A1 (enExample) |
| CO (1) | CO2023008866A2 (enExample) |
| IL (2) | IL303127A (enExample) |
| MX (2) | MX2023005707A (enExample) |
| MY (1) | MY209195A (enExample) |
| PE (1) | PE20231659A1 (enExample) |
| TW (3) | TW202620039A (enExample) |
| WO (1) | WO2022129526A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| AR127945A1 (es) | 2021-12-13 | 2024-03-13 | Novo Nordisk As | Formulaciones farmacéuticas que comprenden un agonista del receptor de amilina, un agonista del receptor de glp-1 y una ciclodextrina |
| CN118973602A (zh) | 2022-03-30 | 2024-11-15 | 诺和诺德股份有限公司 | 配制方法 |
| WO2024022465A1 (zh) * | 2022-07-29 | 2024-02-01 | 杭州九源基因工程有限公司 | 一种人胰淀素多肽衍生物及其用途 |
| CN119654159A (zh) * | 2022-08-05 | 2025-03-18 | 印第安纳大学研究与技术公司 | 胰高血糖素样肽-1受体拮抗剂 |
| US12116388B2 (en) | 2022-12-22 | 2024-10-15 | Novo Nordisk A/S | Amylin receptor agonists |
| CN120731085A (zh) * | 2023-03-02 | 2025-09-30 | 甘李药业股份有限公司 | 一种glp-1化合物的医药用途 |
| AU2024305247A1 (en) | 2023-06-15 | 2025-12-11 | Novo Nordisk A/S | Pharmaceutical formulations of an amylin receptor agonist and a glp-1 receptor agonist comprising a cyclodextrin |
| TWI926512B (zh) * | 2023-11-30 | 2026-05-21 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1、gip及澱粉素受體之三重促效劑 |
| TWI913094B (zh) * | 2024-01-29 | 2026-01-21 | 免疫功坊股份有限公司 | 適合舌下給藥的類升糖素肽-1受體促效劑肽的藥學配方 |
| EP4603080A1 (en) | 2024-02-16 | 2025-08-20 | Adocia | Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| EP4603079A1 (en) | 2024-02-16 | 2025-08-20 | Adocia | Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| EP4721760A1 (en) | 2024-10-07 | 2026-04-08 | Adocia | Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| WO2025172605A1 (en) | 2024-02-16 | 2025-08-21 | Adocia | Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| EP4684801A1 (en) | 2024-07-23 | 2026-01-28 | Adocia | Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| EP4721761A1 (en) | 2024-10-07 | 2026-04-08 | Adocia | Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| EP4684802A1 (en) | 2024-07-23 | 2026-01-28 | Adocia | Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| WO2025172606A1 (en) | 2024-02-16 | 2025-08-21 | Adocia | Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| US20260091086A1 (en) * | 2024-05-20 | 2026-04-02 | Medimmune Limited | Polypeptide combinations and uses thereof |
| WO2025264979A1 (en) * | 2024-06-21 | 2025-12-26 | I2O Therapeutics, Inc. | Compositions comprising pharmaceutically acceptable salts and other derivatives of dual glp-1/amylin receptor agonists and uses thereof |
| WO2026008836A1 (en) * | 2024-07-05 | 2026-01-08 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| WO2026013265A1 (en) | 2024-07-12 | 2026-01-15 | Novo Nordisk A/S | Novel dipeptide acylating agents |
| WO2026067799A1 (zh) * | 2024-09-30 | 2026-04-02 | 杭州先为达生物科技股份有限公司 | Glp-1受体和胰淀素受体的共激动剂 |
| KR102991397B1 (ko) * | 2024-11-29 | 2026-07-21 | 노보 노르디스크 에이/에스 | Glp-1, gip, 및 아밀린 수용체의 삼중작용제 및 이의 용도 |
| WO2026124639A1 (zh) * | 2024-12-12 | 2026-06-18 | 深圳信立泰药业股份有限公司 | 多重受体共激动剂及其制备方法与应用 |
| CN120305390B (zh) * | 2025-06-18 | 2025-10-03 | 杭州思诺达医药科技有限责任公司 | 一种降血糖的药物制剂 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08501942A (ja) | 1992-09-30 | 1996-03-05 | ザイモジェネティクス，インコーポレイティド | ヒト カルシトニン レセプター |
| EP1670515A2 (en) | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| KR20140011431A (ko) * | 2004-02-11 | 2014-01-28 | 아밀린 파마슈티칼스, 엘엘씨. | 선택가능한 특성을 갖는 하이브리드 폴리펩티드 |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| EP1922336B1 (en) | 2005-08-11 | 2012-11-21 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
| AU2007227202B2 (en) | 2006-03-21 | 2013-08-22 | Amylin Pharmaceuticals, Llc | Peptide-peptidase inhibitor conjugates and methods of using same |
| US20100261637A1 (en) | 2007-09-05 | 2010-10-14 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| WO2010118384A2 (en) | 2009-04-10 | 2010-10-14 | Amylin Pharmaceuticals, Inc. | Amylin agonist compounds for estrogen-deficient mammals |
| JP2013511287A (ja) * | 2009-11-23 | 2013-04-04 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | ポリペプチド・コンジュゲート |
| US20120329711A1 (en) * | 2009-12-16 | 2012-12-27 | Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| US20110312881A1 (en) | 2009-12-21 | 2011-12-22 | Amunix, Inc. | Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases |
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| WO2012162547A2 (en) | 2011-05-25 | 2012-11-29 | Amylin Pharmaceuticals, Inc. | Long duration dual hormone conjugates |
| WO2012160212A1 (en) * | 2011-05-25 | 2012-11-29 | Camurus Ab | Peptide controlled-release formulations |
| EP2718315B1 (en) | 2011-06-10 | 2017-12-27 | Novo Nordisk A/S | Pramlintide derivatives |
| MX354705B (es) * | 2011-09-23 | 2018-03-16 | Novo Nordisk As | Analogos de glucagon novedosos. |
| KR102072202B1 (ko) | 2012-03-22 | 2020-01-31 | 노보 노르디스크 에이/에스 | Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조 |
| WO2013189988A1 (en) | 2012-06-20 | 2013-12-27 | Novo Nordisk A/S | Tablet formulation comprising a peptide and a delivery agent |
| AU2014283221A1 (en) | 2013-06-20 | 2015-12-03 | Novo Nordisk A/S | GLP-1 derivatives and uses thereof |
| CN104558198A (zh) | 2014-07-25 | 2015-04-29 | 成都贝爱特生物科技有限公司 | GLP-1类似物和amylin类似物的融合蛋白制备及其用途 |
| CN106687474A (zh) | 2014-09-04 | 2017-05-17 | 诺和诺德股份有限公司 | 新型胰淀素和降钙素受体激动剂 |
| JP6730278B2 (ja) | 2014-11-27 | 2020-07-29 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体及びその使用 |
| EP3233898A1 (en) | 2014-12-17 | 2017-10-25 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| AR103954A1 (es) * | 2015-03-18 | 2017-06-14 | Zealand Pharma As | Análogos de amilina |
| CN105367664B (zh) * | 2015-11-04 | 2019-09-20 | 成都贝爱特生物科技有限公司 | 激活GLP-1受体和Amylin受体双功能作用的融合蛋白制备及其用途 |
| BR102015031283A2 (pt) | 2015-12-14 | 2018-09-18 | Univ Rio De Janeiro | Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento |
| ES2828526T3 (es) | 2016-11-07 | 2021-05-26 | Novo Nordisk As | Esteres activos DCHBS de compuestos PEG y sus usos |
| CN108424460A (zh) | 2017-02-13 | 2018-08-21 | 成都贝爱特生物科技有限公司 | GLP-1类似物和davalintide类似物的融合蛋白制备及其用途 |
| AR114353A1 (es) | 2018-02-02 | 2020-08-26 | Novo Nordisk As | Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| CN115461044B (zh) | 2020-04-29 | 2025-06-10 | 诺和诺德股份有限公司 | 包含glp-1激动剂和组氨酸的固体组合物 |
-
2021
- 2021-12-16 TW TW115100762A patent/TW202620039A/zh unknown
- 2021-12-16 TW TW115100764A patent/TW202615455A/zh unknown
- 2021-12-16 TW TW110147258A patent/TWI850611B/zh active
- 2021-12-17 IL IL303127A patent/IL303127A/en unknown
- 2021-12-17 EP EP21831066.2A patent/EP4263581A1/en active Pending
- 2021-12-17 CN CN202610110158.7A patent/CN121975020A/zh active Pending
- 2021-12-17 AU AU2021403851A patent/AU2021403851B2/en active Active
- 2021-12-17 KR KR1020237002759A patent/KR102667196B1/ko active Active
- 2021-12-17 MY MYPI2023002756A patent/MY209195A/en unknown
- 2021-12-17 IL IL325793A patent/IL325793A/en unknown
- 2021-12-17 KR KR1020247015294A patent/KR102884383B1/ko active Active
- 2021-12-17 JP JP2023528227A patent/JP7554928B2/ja active Active
- 2021-12-17 CA CA3201088A patent/CA3201088A1/en active Pending
- 2021-12-17 KR KR1020257037256A patent/KR20250165665A/ko active Pending
- 2021-12-17 MX MX2023005707A patent/MX2023005707A/es unknown
- 2021-12-17 WO PCT/EP2021/086494 patent/WO2022129526A1/en not_active Ceased
- 2021-12-17 CN CN202610109721.9A patent/CN121991249A/zh active Pending
- 2021-12-17 CN CN202180085551.0A patent/CN116669753A/zh active Pending
- 2021-12-17 CN CN202610110419.5A patent/CN121991202A/zh active Pending
- 2021-12-17 PE PE2023001880A patent/PE20231659A1/es unknown
-
2022
- 2022-12-19 US US18/084,088 patent/US12054528B2/en active Active
-
2023
- 2023-05-16 MX MX2025000872A patent/MX2025000872A/es unknown
- 2023-06-13 CL CL2023001714A patent/CL2023001714A1/es unknown
- 2023-07-04 CO CONC2023/0008866A patent/CO2023008866A2/es unknown
-
2024
- 2024-02-29 US US18/591,754 patent/US20240279299A1/en active Pending
-
2025
- 2025-10-09 AU AU2025248685A patent/AU2025248685A1/en active Pending
- 2025-12-04 US US19/409,120 patent/US20260132182A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7554928B2 (ja) | Ｇｌｐ－１およびアミリン受容体の共作動薬 | |
| ES2514615T3 (es) | Proteínas de dominio Kunitz inhibidores de calicreína y ácidos nucleicos que codifican las mismas | |
| CA2320371C (en) | Inotropic and diuretic effects of exendin and glp-1 | |
| JP5969461B2 (ja) | Ｇｌｐ−１受容体作動薬とガストリンとのペプチド複合体及びその使用 | |
| ES2614603T3 (es) | Procedimiento de administración de moléculas GLP-1 | |
| CA2277112C (en) | Use of exendins and agonists thereof for the reduction of food intake | |
| JP2019504055A5 (enExample) | ||
| JP2023526973A5 (enExample) | ||
| JP2022509568A5 (enExample) | ||
| AR038102A1 (es) | Analogos extendidos de peptido 1 de tipo glucagon | |
| PT1181043E (pt) | ''utilização de exendinas e seus agonistas para o tratamento de diabetes mellitus gestacional'' | |
| JP2008514624A5 (enExample) | ||
| JP2012504619A5 (enExample) | ||
| GB2640988A (en) | Amylin analogues | |
| JPWO2022202816A5 (enExample) | ||
| US20250074964A1 (en) | Stable glp-1 analogs for the treatment of human disease and disorders | |
| CN1700920A (zh) | 羟基甾族化合物的预防和治疗应用 | |
| Parker et al. | Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP (3–42) and GLP-1 (9–36) amide, on insulin secretion and glucose homeostasis in ob/ob mice | |
| RU2025117213A (ru) | Аналоги амилина | |
| JP2025542410A5 (enExample) | ||
| ES2550536T3 (es) | Motivos de la familia de polipéptidos pancreáticos, polipéptidos y métodos que los comprenden | |
| RU2025125845A (ru) | Соединения | |
| TH51594A (th) | สารประกอบเปปไทด์-1 แอนาลอกคล้ายกับกลูคากอน | |
| BR122024023347A2 (pt) | Coagonistas dos receptores glp-1 e amilina, formulação farmacêutica compreendendo os ditos coagonistas e uso terapêutico dos mesmos | |
| TH65071A (th) | เพพไทด์ควบคุม และอนุเคราะห์ hiv แอนติเจน องค์ประกอบวัคซีนชุดสำเร็จรูปอิมมูโนแอสเสย์และวิธีการของการตรวจหาแอนติบอดีที่ถูกชักนำโดย hiv |